PTX Pernix Therapeutics Holdings, I

4.11
0  -2%
Previous Close 4.20
Open 4.18
Price To book 0.00
Market Cap 41.16M
Shares 10,015,000
Volume 251,468
Short Ratio 1.15
Av. Daily Volume 731,684

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved May 15, 2015.
TREXIMET
Adolescent migraine patients

Latest News

  1. Rennova Health and Pernix Therapeutics Both Led In the Pharma Arena with Significant Share Price Jumps
  2. ETFs with exposure to Pernix Therapeutics Holdings, Inc. : April 19, 2017
  3. Platinex Inc.-Proposed Private Placement
  4. Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q4, 2016 By the Numbers : April 5, 2017
  5. Today's Research Reports on Biotech Stocks to Watch: Catalyst Biosciences and Pernix Therapeutics
  6. Edited Transcript of PTX earnings conference call or presentation 28-Mar-17 8:30pm GMT
  7. Pernix Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
  8. Pernix: An Investor's Rationale to Staying Long
  9. Pernix Therapeutics to Report Fourth Quarter and Year-End 2016 Financial Results on Tuesday, March 28
  10. Biotech's Rise Shows No Sign of Slowing Dow in 2017: Today's Reports on Pernix Therapeutics and Brainstorm Cell Therapeutics
  11. Pernix Therapeutics Prevails in Zohydro® ER ANDA Litigation
  12. Pernix Therapeutics Provides Update on Arbitration
  13. ETFs with exposure to Pernix Therapeutics Holdings, Inc. : January 20, 2017
  14. Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q3, 2016 By the Numbers : January 5, 2017
  15. Blog Coverage Teva Reports Positive Outcome for the European Label for COPAXONE®; Replaces Generics Head
  16. Drug Makers Stocks Under Scanner -- Pernix Therapeutics, Novo Nordisk, Synergy Pharma, and Apricus Biosciences